

# Physician's Orders

## RITUXIMAB OR BIOSIMILAR

### WEEKLY TIMES 4 DOSES - ADULT, OUTPATIENT, INFUSION CENTER

#### Page 1 to 3

Anticipated Infusion Date \_\_\_\_\_ ICD 10 Code with Description \_\_\_\_\_

Height \_\_\_\_\_ (cm) Weight \_\_\_\_\_ (kg) Allergies \_\_\_\_\_

#### Site of Service

- |  |  |                                       |  |
|--|--|---------------------------------------|--|
| <input type="checkbox"/> CH Gerber           | <input type="checkbox"/> CH Lemmen Holton (GR) | <input type="checkbox"/> CH Pennock   | <input type="checkbox"/> CH Greenville |
| <input type="checkbox"/> CH Helen DeVos (GR) | <input type="checkbox"/> CH Ludington          | <input type="checkbox"/> CH Reed City | <input type="checkbox"/> CH Zeeland    |
| <input type="checkbox"/> CH Blodgett (GR)    |  |                                       |  |

#### Provider Specialty

- |   |   |   |                                       |
|---|---|---|---------------------------------------|
| <input type="checkbox"/> Allergy/Immunology | <input type="checkbox"/> Infectious Disease           | <input type="checkbox"/> OB/GYN         | <input type="checkbox"/> Rheumatology |
| <input type="checkbox"/> Cardiology         | <input type="checkbox"/> Internal Med/Family Practice | <input type="checkbox"/> Other          | <input type="checkbox"/> Surgery      |
| <input type="checkbox"/> Gastroenterology   | <input type="checkbox"/> Nephrology                   | <input type="checkbox"/> Otolaryngology | <input type="checkbox"/> Urology      |
| <input type="checkbox"/> Genetics           | <input type="checkbox"/> Neurology                    | <input type="checkbox"/> Pulmonary      | <input type="checkbox"/> Wound Care   |

#### Treatment Intent

- |                                       |                                      |                                       |                                     |
|---------------------------------------|--------------------------------------|---------------------------------------|-------------------------------------|
| <input type="checkbox"/> Conditioning | <input type="checkbox"/> Curative    | <input type="checkbox"/> Mobilization | <input type="checkbox"/> Supportive |
| <input type="checkbox"/> Control      | <input type="checkbox"/> Maintenance | <input type="checkbox"/> Palliative   |                                     |

#### Cycle 1

##### One dose every 7 days x 4 doses on day 1, 8, 15, 22

##### Provider Reminder

##### ☒ ONC PROVIDER REMINDER 2

Confirm that the appropriate informed consents have been signed and are in the medical record.

##### Appointment Requests

##### ☒ ONCBCN CALCULATED LENGTH INFUSION APPOINTMENT REQUEST 1

##### Labs

##### ☒ COMPLETE BLOOD COUNT (CBC) W/DIFFERENTIAL

##### ☒ Pregnancy tests recommended for Females aged 12 to 60 with Uterus intact.

Please order as appropriate for clinical presentation

Interval: Once Selection conditions: Patient could become pregnant

##### ☐ HCG, QUANTITATIVE

##### ☒ ONC PROVIDER REMINDER

Review prior hepatitis labs and consider repeat screening as indicated.

##### ☒ HEPATITIS PANEL

Selection conditions: Hides NCCN Hepatitis Screening orders in background if the patient has had a completed hepatitis lab within the last 365 days.

##### ☒ HEP B CORE TOTAL AB

Selection conditions: Hides NCCN Hepatitis Screening orders in background if the patient has had a completed hepatitis lab within the last 365 days.

##### Vitals

##### ☒ VITAL SIGNS

RITUXIMAB - Dose 1 &amp; 2: Vital signs every 15 minutes x 2 hours, then hourly throughout infusion. Subsequent doses: Vital signs with rate changes.

##### Nursing Orders

##### ☒ HYPERSENSITIVITY REACTION ADULT ONCOLOGY PROTOCOL

##### ☒ ONC NURSING COMMUNICATION 100

May Initiate IV Catheter Patency Adult Protocol

# RITUXIMAB OR BIOSIMILAR WEEKLY TIMES 4 DOSES - ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED) Page 2 to 3

## Treatment Parameters

### ☒ **ONC MONITORING AND HOLD PARAMETERS 3**

May proceed with treatment if hepatitis B core antibody and surface antigen labs have been resulted prior to the first dose, and the results are negative.

## Pre-Medications

### ☐ **acetaminophen (Tylenol) tablet 650 mg**

Dose: 650 mg Route: Oral Once Instructions: Administer 30 minutes prior to rituximab.

### ☐ **diphenhydrAMINE (Benadryl) capsule 50 mg**

Dose: 50 mg Route: Oral Once Instructions: Administer 30 minutes prior to rituximab.

## Pre-Medications

### ☒ **ONC PROVIDER REMINDER 7**

HISTORY OF INFUSION REACTION: consider adding CORTICOSTEROID pre-medication prior to riTUXimab or biosimilar

### ☐ **dexAMETHasone (Decadron) injection 10 mg**

Dose: 10 mg Route: Intravenous Once over 5 Minutes for 1 dose

Instructions:

For patient with a history of reaction to riTUXimab or biosimilar. Administer 30 minutes prior to start of riTUXimab or biosimilar.

### ☐ **methyIPREDNISolone sodium succinate (SOLU-Medrol) injection 125 mg**

Dose: 125 mg Route: Intravenous Once for 1 dose

Instructions:

For patient with a history of reaction to riTUXimab or biosimilar. Administer 30 minutes prior to start of riTUXimab or biosimilar.

### ☐ **hydrocortisone sodium succinate (PF) (Solu-CORTEF) injection 100 mg**

Dose: 100 mg Route: Intravenous Once for 1 dose

Instructions:

For patient with a history of reaction to riTUXimab or biosimilar. Administer 30 minutes prior to start of riTUXimab or biosimilar.

## Monoclonal Antibody / Biotherapy

### ☒ **riTUXimab-pvvr (RUXIENCE) 2 mg/mL infusion 375 mg/m2**

Dose: 375 mg/m2 Route: Intravenous Titrate @ 25-200 mL/hr for 1 dose

Instructions:

Before start of riTUXimab-pvvr, infusion, prime 0.9% sodium chloride 250 mL with primary tubing and have available at bedside in case of hypersensitivity or infusion reaction. Do NOT connect this saline with any other intravenous drugs, fluids, or blood products.

Start infusion at 50 mg/hr (25 mL/hr). For patients tolerating the infusion well, the rate of infusion may be increased in increments of 50 mg/hr (25 mL/hr) at intervals of 30 minutes to a maximum rate of 400 mg/hr (200 mL/hr).

SUBSEQUENT INFUSIONS: If patient tolerated initial infusion, start at 100 mg/hour (50 mL/hr); if there is no infusion-related reaction, increase the rate by 100 mg/hour (50 mL/hr) increments every 30 minutes, to a maximum rate of 400 mg/hour (200 mL/hr)

### ☐ **riTUXimab-abbs (TRUXIMA) 2 mg/mL infusion 375 mg/m2**

Dose: 375 mg/m2 Route: Intravenous Titrate @ 25-200 mL/hr for 1 dose

Instructions:

Before start of riTUXimab-abbs, infusion, prime 0.9% sodium chloride 250 mL with primary tubing and have available at bedside in case of hypersensitivity or infusion reaction. Do NOT connect this saline with any other intravenous drugs, fluids, or blood products.

Start infusion at 50 mg/hr (25 mL/hr). For patients tolerating the infusion well, the rate of

# RITUXIMAB OR BIOSIMILAR WEEKLY TIMES 4 DOSES -

## ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED)

Page 3 to 3

infusion may be increased in increments of 50 mg/hr (25 mL/hr) at intervals of 30 minutes to a maximum rate of 400 mg/hr (200 mL/hr).

SUBSEQUENT INFUSIONS: If patient tolerated initial infusion, start at 100 mg/hour (50 mL/hr); if there is no infusion-related reaction, increase the rate by 100 mg/hour (50 mL/hr) increments every 30 minutes, to a maximum rate of 400 mg/hour (200 mL/hr)

### ☐ **riTUXimab (RITUXAN) 2 mg/mL infusion 375 mg/m2**

Dose: 375 mg/m2 Route: Intravenous Titrate @ 25-200 mL/hr for 1 dose

#### Instructions:

Before start of riTUXimab, infusion, prime 0.9% sodium chloride 250 mL with primary tubing and have available at bedside in case of hypersensitivity or infusion reaction. Do NOT connect this saline with any other intravenous drugs, fluids, or blood products.

Start infusion at 50 mg/hr (25 mL/hr). For patients tolerating the infusion well, the rate of infusion may be increased in increments of 50 mg/hr (25 mL/hr) at intervals of 30 minutes to a maximum rate of 400 mg/hr (200 mL/hr).

SUBSEQUENT INFUSIONS: If patient tolerated initial infusion, start at 100 mg/hour (50 mL/hr); if there is no infusion-related reaction, increase the rate by 100 mg/hour (50 mL/hr) increments every 30 minutes, to a maximum rate of 400 mg/hour (200 mL/hr)

### ☐ **riTUXimab-arrx (RIABNI) 2 mg/mL infusion 375 mg/m2**

Dose: 375 mg/m2 Route: Intravenous Titrate @ 25-200 mL/hr for 1 dose

#### Instructions:

Before start of riTUXimab-arrx infusion, prime 0.9% sodium chloride 250 mL with primary tubing and have available at bedside in case of hypersensitivity or infusion reaction. Do NOT connect this saline with any other intravenous drugs, fluids, or blood products.

Start infusion at 50 mg/hr (25 mL/hr). For patients tolerating the infusion well, the rate of infusion may be increased in increments of 50 mg/hr (25 mL/hr) at intervals of 30 minutes to a maximum rate of 400 mg/hr (200 mL/hr).

SUBSEQUENT INFUSIONS: If patient tolerated initial infusion, start at 100 mg/hour (50 mL/hr); if there is no infusion-related reaction, increase the rate by 100 mg/hour (50 mL/hr) increments every 30 minutes, to a maximum rate of 400 mg/hour (200 mL/hr)

#### Supportive Care

##### ☒ **prochlorperazine (COMPAZINE) tablet 10 mg**

Dose: 10 mg Route: Oral Every 6 hours PRN

Instructions: Use 1st line for nausea/vomiting for patients able to tolerate oral medications.

##### ☒ **prochlorperazine (COMPAZINE) injection 10 mg**

Dose: 10 mg Route: Intravenous Every 6 hours PRN over 5 Minutes

Instructions: Use 1st line for nausea/vomiting for patients unable to tolerate oral medications.

##### ☒ **ondansetron (ZOFTRAN-ODT) disintegrating tablet 8 mg**

Dose: 8 mg Route: Oral Every 8 hours PRN

Instructions: Use 2nd line for Nausea/Vomiting. May give IV if unable to tolerate PO.

##### ☒ **ondansetron (ZOFTRAN) injection 8 mg**

Dose: 8 mg Route: Intravenous Every 8 hours PRN over 5 Minutes

Instructions: Use 2nd line for Nausea/Vomiting. May give IV if unable to tolerate PO.

Telephone order/Verbal order documented and read-back completed. Practitioner's initials \_\_\_\_\_

**NOTE:** Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:		Pager #	Physician	Physician
TIME	DATE	TIME	DATE	TIME	DATE			
Sign		R.N. Sign		Physician Print				Sign

EPIC VERSION DATE: 07/16/20

X25307 (4/25) – Page 3 of 3 © Corewell Health